Kodiak Sciences Q3 net loss $50M; GLOW study shows tarcocimab 29-fold improvement

Kodiak Sciences Inc.

2023-Q3 EPS reported -$3.84

Net loss $50.0M ($0.95/shr) vs $77.0M ($1.47) in Q3 2022; cash $345.7M.
R&D expenses fell to $36.2M from $61.7M due to development pause and forfeitures.
GLOW phase 3: 41.1% tarcocimab patients had ≥2-step DRSS improvement vs 1.4% sham (p<0.0001).
89% risk reduction in sight-threatening complications; plan to reboot tarcocimab for single BLA.
KSI-501 phase 1 enrollment complete; data expected Q1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.